Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Insights
Menu

Microsoft doubles down on AI in health

AI Biotech/Diagnostics: Other Innovation Patent Forecast®

February 6, 2020

Microsoft is no stranger to the AI biotech space, with a handful of granted patents spanning neurological, ophthalmic, and musculoskeletal medicines. Now the company wants to dive deeper.

This week, Microsoft announced a $40 million AI initiative aimed at research on global health challenges called AI for Health. The program will equip academia and non-profit research groups in their efforts to develop diagnostics, treatments, and preventative measures, specifically in health for under-served populations.

Previously, Microsoft entered a partnership with Swiss pharmaceutical company Novartis to equip all of their associates with AI tools. Now, the Novartis foundation, along with the Fred Hutchinson Cancer Research Center, Seattle Children's Research Institute, PATH, Intelligent Retinal Imaging Systems and the international development organization BRAC are among the first grantees of AI for Health.


Relevant Patent Documents

Patent US10154191  

Patent US10083233  

Patent US10426551  

Article Source Link

Fierce Biotech


View Patent Forecast®

Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.

AI Biotech/Diagnostics: Other Innovation   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.



301